Medigene AG Logo

Medigene AG

Clinical-stage immuno-oncology firm developing TCR-engineered T cell therapies for solid tumors.

MDG1 | F

Overview

Corporate Details

ISIN(s):
DE000A40ESG2
LEI:
391200I33JD2DKZGDX06
Country:
Germany
Address:
Lochhamer Straße 11, 82152 Planegg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Medigene AG is a clinical-stage immuno-oncology platform company focused on developing differentiated T-cell receptor (TCR)-engineered T cell (TCR-T) therapies to treat solid tumors. The company's proprietary end-to-end platform is designed to generate optimal affinity 3S (sensitive, specific, safe) TCRs that can be applied across various modalities, including TCR-T cell engagers and TCR-natural killer cell therapies. Its pipeline includes candidates such as MDG1015, a 3rd generation TCR-T therapy. According to company announcements, insolvency proceedings for the company's assets were opened by court order on August 1, 2025.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2024-10-16 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-09-18 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-08-14 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 183.1 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-05-06 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 789.0 KB
2024-03-28 00:00
Annual Report
English 9.9 MB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-02-23 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 2.1 KB
2023-08-17 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2023 bis zum 30.0…
German 171.2 KB
2023-04-26 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 665.8 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.4 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2022-08-03 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 183.3 KB
2022-05-02 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 779.5 KB

Automate Your Workflow. Get a real-time feed of all Medigene AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medigene AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea 034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan 4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden CINPHA
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway CRNA
CJ Bioscience Logo
Develops microbiome therapeutics for oncology & IBD using an AI drug discovery platform.
South Korea 311690
CKD Bio Corp. Logo
Develops and manufactures probiotics & APIs using fermentation, also offering cGMP CMO services.
South Korea 063160
CMG Pharmaceutical Co., Ltd. Logo
Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.
South Korea 058820
co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany CNW
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480

Talk to a Data Expert

Have a question? We'll get back to you promptly.